Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies.
Nat Microbiol
; 8(6): 1051-1063, 2023 06.
Article
en En
| MEDLINE
| ID: mdl-37188812
ABSTRACT
Human monoclonal antibodies (mAbs) that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been isolated from convalescent individuals and developed into therapeutics for SARS-CoV-2 infection. However, therapeutic mAbs for SARS-CoV-2 have been rendered obsolete by the emergence of mAb-resistant virus variants. Here we report the generation of a set of six human mAbs that bind the human angiotensin-converting enzyme-2 (hACE2) receptor, rather than the SARS-CoV-2 spike protein. We show that these antibodies block infection by all hACE2 binding sarbecoviruses tested, including SARS-CoV-2 ancestral, Delta and Omicron variants at concentrations of ~7-100 ng ml-1. These antibodies target an hACE2 epitope that binds to the SARS-CoV-2 spike, but they do not inhibit hACE2 enzymatic activity nor do they induce cell-surface depletion of hACE2. They have favourable pharmacology, protect hACE2 knock-in mice against SARS-CoV-2 infection and should present a high genetic barrier to the acquisition of resistance. These antibodies should be useful prophylactic and treatment agents against any current or future SARS-CoV-2 variants and might be useful to treat infection with any hACE2-binding sarbecoviruses that emerge in the future.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo
/
COVID-19
Idioma:
En
Revista:
Nat Microbiol
Año:
2023
Tipo del documento:
Article